B+
Bull case
25%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
PHIO
PhioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive read is that PHIO has finished the clinical phase of PH-762 dose escalation, reported favorable safety/pathology framing, secured toxicology and U.S. cGMP supply agreements, and still guides to runway into H1 2027, leaving room for a meaningful re-rate if FDA feedback supports a credible next trial design [#PR-EARNINGS-2026-05-08].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Cash fell to about $17 million by March 31, 2026 and the April 2026 ATM adds dilution risk if external funding is needed sooner than hoped.
Momentum
87
Value
59
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.85 · Bull $1.80 · Bear $0.40Analysis 2026-06-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $14.00
Why
Momentum87 · Δ7d -
Value59 · Δ7d 0.0
Sentiment54 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Cash fell to about $17 million by March 31, 2026 and the April 2026 ATM adds dilution risk if external funding is needed sooner than hoped.
- • Coverage is thin and recent communications were largely company-promoted investor events, which raises volatility and lowers confidence in external validation.
- • The cautious read is that the key efficacy package is still awaiting final analysis, FDA interaction could add work or time, R&D spending is rising as PH-762 advances, and the ATM creates a visible dilution path if capital needs outrun sentiment [#PR-EARNINGS-2026-05-08].
Catalyst clock
2026-06-30
PH-762 FDA interaction on next-step study design
Lead driver: Sentiment · See AI snapshot
Momentum
87
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+1.0
Sentiment
54
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 86.7 / Value 58.8 / Sentiment 54.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.40
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$12.31M
Beta
0.93
Shares Out
11.62M
P/E (TTM) · Derived
-0.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.85
Rev YoY
-100.0%
EPS YoY
-21.1%
Gross Margin
-
Op Margin
-
Net Debt
-$21.03M
Current Ratio
8.39
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data